Latest price of larotrectinib in 2024

Larotrectinib is a revolutionary anti-cancer drug that belongs to the category of targeted therapy drugs and is used to treat certain cancer patients, especially those carrying specific gene mutations. It is unique in that it targets specific genetic mutations in cancer cells, rather than the type of cancer targeted by traditional treatments.

Although larotrectinib has been launched in the domestic market, it has not yet entered the medical insurance system. Since it has not been on the market for a long time in China, it may be difficult to purchase it in the hospital. Therefore, it is recommended that you consult the local hospital pharmacy for the latest information. In the international market, larotinib has two types: original drug and generic drug for patients to choose from. Original drugs include versions from Germany, the United States, Europe and Hong Kong, China, with prices ranging from RMB 10,000 to RMB 20,000. On the other hand, generic drugs are relatively more affordable. The prices of generic drugs in Laos and Bangladesh are only about two to three thousand yuan. The important thing is that whether it is an original drug or a generic drug, the drug ingredients are basically the same.

Larotinib is mainly used to treat TRK gene fusion-positive malignant tumors. TRKGene fusion is a rare but clinically significant genetic mutation that contributes to the development and growth of tumors. This gene fusion occurs in a variety of cancer types, including tumors in children and adults.

The uniqueness of this drug lies in its targeting. It can directly interfere with the abnormal signaling pathways of cancer cells, thereby inhibiting the growth and spread of tumors. Compared with traditional radiotherapy and chemotherapy, larotrectinib has fewer side effects on patients and is more effective.

Clinical trials have shown that larotrectinib has shown significant therapeutic effects in the treatment of TRK gene fusion-positive tumor patients. Many patients show signs of significant tumor shrinkage or even complete disappearance after treatment, with fewer adverse effects.

However, it is important to note that larotrectinib is not suitable for all types of cancer, and its use must be based on genetic testing results and physician recommendations. Before starting use, doctors will perform genetic testing on patients to determine whether aTRKgene fusion is present. Doctors will consider prescribing larotrectinib only if the patient is confirmed to have the gene mutation.